Novo Nordisk A/S (NYSE:NVO) Shares Bought by Asio Capital LLC

Asio Capital LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 5.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,301 shares of the company’s stock after buying an additional 266 shares during the period. Asio Capital LLC’s holdings in Novo Nordisk A/S were worth $456,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Carolina Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $48,000. Finally, M&R Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Up 8.4 %

NYSE:NVO opened at $87.94 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $95.35 and its 200-day moving average is $115.17. The firm has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.